Accelerate Diagnostics Stock Performance
| AXDX Stock | USD 1.66 0.05 3.11% |
The firm shows a Beta (market volatility) of -0.61, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Accelerate Diagnostics are expected to decrease at a much lower rate. During the bear market, Accelerate Diagnostics is likely to outperform the market. At this point, Accelerate Diagnostics has a negative expected return of -0.19%. Please make sure to confirm Accelerate Diagnostics' total risk alpha, as well as the relationship between the kurtosis and market facilitation index , to decide if Accelerate Diagnostics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Accelerate Diagnostics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's fundamental indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Last Split Factor 1:10 | Last Split Date 2023-07-12 |
1 | Acquisition by Ogilvie Marran H. of 66667 shares of Accelerate Diagnostics subject to Rule 16b-3 | 09/10/2024 |
2 | Disposition of 4737 shares by Regan Jennifer of Accelerate Diagnostics subject to Rule 16b-3 | 09/11/2024 |
3 | Accelerate Diagnostics Now Covered by Analysts at StockNews.com | 10/08/2024 |
4 | Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results - StockTitan | 10/25/2024 |
5 | Accelerate Diagnostics Q3 Earnings Preview | 11/06/2024 |
6 | Accelerate Diagnostics Q3 Earnings Snapshot | 11/07/2024 |
7 | Accelerate Diagnostics Inc Q3 2024 Earnings Call Highlights Strategic Advances Amid ... | 11/08/2024 |
8 | Earnings call Accelerate Diagnostics Q3 results and FDA clearances | 11/11/2024 |
| Begin Period Cash Flow | 34.9 M |
Accelerate |
Accelerate Diagnostics Relative Risk vs. Return Landscape
If you would invest 197.00 in Accelerate Diagnostics on September 2, 2024 and sell it today you would lose (31.00) from holding Accelerate Diagnostics or give up 15.74% of portfolio value over 90 days. Accelerate Diagnostics is currently does not generate positive expected returns and assumes 4.031% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Accelerate, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Accelerate Diagnostics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Accelerate Diagnostics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Accelerate Diagnostics, and traders can use it to determine the average amount a Accelerate Diagnostics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0465
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AXDX |
Estimated Market Risk
| 4.03 actual daily | 35 65% of assets are more volatile |
Expected Return
| -0.19 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Accelerate Diagnostics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Accelerate Diagnostics by adding Accelerate Diagnostics to a well-diversified portfolio.
Accelerate Diagnostics Fundamentals Growth
Accelerate Stock prices reflect investors' perceptions of the future prospects and financial health of Accelerate Diagnostics, and Accelerate Diagnostics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Accelerate Stock performance.
| Return On Asset | -0.76 | ||||
| Operating Margin | (2.88) % | ||||
| Current Valuation | 79.63 M | ||||
| Shares Outstanding | 25.04 M | ||||
| Price To Earning | (15.18) X | ||||
| Price To Sales | 3.40 X | ||||
| Revenue | 12.06 M | ||||
| Gross Profit | 3.3 M | ||||
| EBITDA | (49.77 M) | ||||
| Net Income | (61.62 M) | ||||
| Cash And Equivalents | 36.77 M | ||||
| Cash Per Share | 0.45 X | ||||
| Total Debt | 39.22 M | ||||
| Debt To Equity | 2.76 % | ||||
| Current Ratio | 4.48 X | ||||
| Book Value Per Share | (1.36) X | ||||
| Cash Flow From Operations | (40.2 M) | ||||
| Earnings Per Share | (2.59) X | ||||
| Market Capitalization | 41.57 M | ||||
| Total Asset | 31.37 M | ||||
| Retained Earnings | (668.86 M) | ||||
| Working Capital | 12.43 M | ||||
| Current Asset | 91.68 M | ||||
| Current Liabilities | 4.45 M | ||||
About Accelerate Diagnostics Performance
Evaluating Accelerate Diagnostics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Accelerate Diagnostics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Accelerate Diagnostics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 127.05 | 120.70 | |
| Return On Tangible Assets | (1.96) | (1.87) | |
| Return On Capital Employed | (2.79) | (2.66) | |
| Return On Assets | (1.96) | (1.87) | |
| Return On Equity | 3.10 | 3.25 |
Things to note about Accelerate Diagnostics performance evaluation
Checking the ongoing alerts about Accelerate Diagnostics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Accelerate Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Accelerate Diagnostics generated a negative expected return over the last 90 days | |
| Accelerate Diagnostics may become a speculative penny stock | |
| Accelerate Diagnostics has high historical volatility and very poor performance | |
| Accelerate Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 12.06 M. Net Loss for the year was (61.62 M) with profit before overhead, payroll, taxes, and interest of 3.3 M. | |
| Accelerate Diagnostics currently holds about 36.77 M in cash with (40.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.45. | |
| Accelerate Diagnostics has a frail financial position based on the latest SEC disclosures | |
| Roughly 41.0% of the company shares are held by company insiders | |
| Latest headline from investing.com: Earnings call Accelerate Diagnostics Q3 results and FDA clearances |
- Analyzing Accelerate Diagnostics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Accelerate Diagnostics' stock is overvalued or undervalued compared to its peers.
- Examining Accelerate Diagnostics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Accelerate Diagnostics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Accelerate Diagnostics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Accelerate Diagnostics' stock. These opinions can provide insight into Accelerate Diagnostics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Accelerate Stock Analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.